NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









OncoResponse

OncoResponse

Private
Seattle, WashingtonHealthcare & Life Scienceshttps://oncoresponse.com/

Last Round

VC Round

May 18, 2023

Total Funding Raised

$169.36M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

OncoResponse is a biotechnology company that develops cancer immunotherapies by leveraging insights from the immune systems of patients who have shown exceptional responses to checkpoint inhibition.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

immuno-oncologymonoclonal antibodyantibody discoverycancer immunotherapybiotech startupdrug discoverysolid tumor treatmentbiopharmaclinical-stage biotechB-cell screeningtherapeutic developmentdrug pipelinebiotech R&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

OncoResponse Comps

Public and private peers based on sector, stage, and business model.

OncoResponse comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

OncoResponse Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundMay 18, 2023
GrantMay 17, 2023
DebtFeb 16, 2022
Series CMar 31, 2021
Series BSep 11, 2018
Series A
Mar 9, 2017

Key People

Founding team and executive leadership

Clifford Stocks

Chief Executive Officer

Executive Team

Chris Russell

Chief Financial Officer

Executive Team

OncoResponse Investors

Notable investors and investment history

OncoResponse investors
InvestorRounds
Redmile GroupSeries C, Series B
GreatPoint VenturesSeries A
InterVestVC Round
Cancer Prevention & Research Institute of TexasGrant
HT Family OfficeSeries B
Magnetar CapitalSeries C
Yonjin CapitalSeries C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 22, 2026

    Monthly visitors grew 70% MoM, from 667 to 1.1K.

  • May 18, 2023

    Received $13M from the Cancer Prevention & Research Institute of Texas.

OncoResponse Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

OncoResponse Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about OncoResponse's valuation, stock price, and market status.

Firmographic Details

HeadquartersSeattle, Washington
Employee Range10
Year Founded2015
Last FundingMay 18, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.